NEW YORK (GenomeWeb News) — LabCorp today said it has licensed DNA-methylation technology from Veridex that may help it develop and market an assay to detect prostate cancer.
 
The reference lab giant said its assay will quantify in human samples the level of the gene GST-Pi, which has been linked to prostate cancer.
 
If the technology is used in conjunction with histopathology testing it may “provide a more sensitive and accurate detection of prostate cancer than histology alone,” LabCorp said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.